tradingkey.logo

RedHill Biopharma Advances Its Groundbreaking Late-Stage Crohn's Disease Program Building On Statistically Significant Positive Rhb-104 Phase 3 Result

ReutersMar 12, 2025 11:08 AM

- Redhill Biopharma Ltd 2RHy.F:

  • REDHILL BIOPHARMA ADVANCES ITS GROUNDBREAKING LATE-STAGE CROHN'S DISEASE PROGRAM BUILDING ON STATISTICALLY SIGNIFICANT POSITIVE RHB-104 PHASE 3 RESULT

Further company coverage: [2RHy.F]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI